Investors & Media

Whats new.

Press releases

Press releases.

Immutep to Present IMP761 Preclinical Results in Global Webcast

March 18th 2019
press releases

Immutep Presents Positive IMP761 Preclinical Results at 14th Congress of European Crohn’s and Colitis Organisation

March 7th 2019
press releases

Immutep receives A$872,351 R&D Tax Incentive

March 7th 2019
press releases

Investor updates

Investor updates.

Investor Update - January 2019

January 31st 2019
investor updates

Investor Update - June 2018

June 19th 2018
investor updates

Investor Update - December 2017

December 21st 2017
investor updates

Analyst reports

Analyst reports.

Maxim - Checkpoints on the Flipside of Immune Oncology... Autoimmune disease - Immutep’s LAG-3 IMP761 Highlighted at ECCO

March 8th 2019
analyst reports

Maxim - Advancing the Second Merck Collaboration, TACTI-002 Doses First Patient

March 6th 2019
analyst reports

LifeSci Capital - Immutep Ltd (IMMP) Presents Updated Data from Ongoing TACTI-Mel Study

March 6th 2019
analyst reports